We partner with manufacturers to move advanced therapies, including CAR-T and bispecifics, safely into outpatient and community settings. We generate the real-world evidence and build the delivery infrastructure that carries a therapy from first-in-human through scaled commercial adoption.
Phase I-IV
We build the clinical and operational infrastructure that accelerates approval, strengthens payer negotiations, and improves access, whether you engage us in early development or after launch.
Pharmacovigilance infrastructure and safety monitoring for in Phase I-III trials.
RWE supports streamlined approvals and label expansion, especially for ambulatory settings.
Evidence feeding payer and access negotiations, patient support infrastructure, and community site enablement.
Scaled access by lowering the barriers to delivery for providers and to access for patients, with ongoing safety and outcomes evidence.
FDA Class II 510(k) for our platform and wearable
EU Class IIa CE-Marked for European approval
SOC 2, ISO 27001, ISO 13485 for security and quality
From Phase I to IV, we run the safety infrastructure that lets advanced therapy trials move into decentralized and ambulatory settings.
Enrollment and site activation are the biggest drivers of trial cost and delay. We take work off sites and off patients so more sites activate faster and more participants enroll and adhere.
Our in-house team works closely with site teams to expedite onboarding and training, confirm site escalation protocols, and ensure high-quality patient education.
By our 24/7 Clinical Command Center without site escalation, freeing site teams to run more patients concurrently.
With tasks and readings. 88% found the kit easy to set up, and adherence holds at 95% even in patients aged 75+, across decentralized and hybrid designs.
After approval, the same infrastructure generates the real-world evidence that improves access to your therapy.
Our infrastructure supports outpatient delivery for CAR-T and bispecifics alike. In Memorial Sloan Kettering’s outpatient program for teclistamab and talquetamab, 89% of patients who started step-up dosing as outpatients successfully reached full dosage.
100% of care-requiring CRS events were preceded by an alarm and escalated the same day. Patients who did not need care generated no clinical alarms.
Rajeeve, Wilkes, Zahradka, et al. Blood. 2025. MSK outpatient bispecific step-up dosing.
In outpatient environments. Passive monitoring surfaces events earlier without over-counting the noise. 83% of patients in outpatient vs. 85% inpatient developed any-grade CRS, no significant difference (P = .89). Any-grade ICANS 34% vs 56%, lower outpatient (P = .02).
Battiwalla et al., Transplant Cell Ther. 2026. axi-cel, DLBCL, n = 143.
Endpoints and safety signals rest on complete data. We protect data completeness across every patient and every feed.
We watch signal quality on every patient and flag when an issue is interfering with data availability.
A per-feed view of connection, battery, and waveform quality, with full signal history, so issues are visible and auditable.
With monitoring protocols when our Clinical Command Center is included in the model.
54 publications and abstracts in the last 36 months, with research partners at leading institutions.
More than 90% of CAR-T therapies delivered safely in outpatient settings with passive monitoring.
89% of patients completed step-up dosing of teclistamab and talquetamab as outpatients.
Passive wearable monitoring through the Current Health platform detected CRS earlier than standard clinical observation.
Roughly 80% of hematologic oncology patients are treated in community settings, not academic medical centers. The advanced therapy opportunity is where those patients are, and we build the infrastructure to reach it.
through safe delivery in community and outpatient settings
by reducing geographic, caregiver, and financial barriers
with provider network development and site activation
(Ahmed et al., Transplant Cell Ther. 2024)
We sit inside your patient support program as the monitoring and clinical layer, removing burden from patients, caregivers, and sites.
The therapies with the highest price tags face the hardest access conversations. We generate the economic and outcomes evidence that turns those conversations in your favor and makes value-based contracts feasible to write.
Internal data reflects the difference between CAR-T and bispecific regimens.
Ambulatory delivery lowers the cost of an episode, and we capture the outcomes and utilization data that quantify it for payers
The hardest part of an outcomes-based agreement is measuring the outcomes, which is exactly what our infrastructure does
Response, adverse events, hospitalizations, and quality of life, generated in real settings and owned by you
An FDA-cleared, CE-marked platform that carries a therapy from Phase I trials through commercial delivery.
54 peer-reviewed publications, proven detection of CRS signals, and the largest outpatient advanced therapy experience base of any platform.
We run the full kit lifecycle and a 24/7 Clinical Command Center, so you get delivery infrastructure and clinical operations, not a device or a dashboard.
Scoped to your program and asset, creating a foundation for purpose-built biomarkers and AI collaborations.
For our platform and wearable
For European approval
For security and quality
